Blood, Lymphatic, Or Bone Marrow Origin Or Derivative Patents (Class 435/372)
  • Patent number: 11566226
    Abstract: This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of NK cells by increasing the expression of specific transcription factors associated with NK cell production.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: January 31, 2023
    Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITED
    Inventors: Hugh J. M. Brady, Matthew Fuchter, Tomasz Kostrzewski
  • Patent number: 11547727
    Abstract: Provided are NK-92 cells expressing a chimeric antigen receptor (CAR). The CAR can comprise an intracellular domain of Fc?RI?. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer or a viral infection, comprising administering to the patient NK-92-CAR cells.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: January 10, 2023
    Assignee: ImmunityBio, Inc.
    Inventors: Laurent H. Boissel, Hans G. Klingemann
  • Patent number: 11541078
    Abstract: Described herein are compositions and methods related to use of cardiosphere-derived cells and their extracellular vesicles, such as exosomes and microvesicles, for achieving anti-aging and rejuvenation. This includes discoveries for effects on heart structure, function, gene expression, and systemic parameters. For animal studies, intra-cardiac injections of neonatal rat CDCs was compared to in old and young rats including evaluation of blood, echocardiographic, haemodynamic and treadmill stress tests. For in vitro studies, human heart progenitors from older donors, or cardiomyocytes from aged rats were exposed to human CDCs or cardiosphere derived cell (CDC) derived exosomes (CDC-XO) from pediatric donors. CDCs and CDC-XOs were capable of effectuating youthful patterns of gene expression in the hearts of old, along with a variant of physiological and function benefits, including elongation of telomere length.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: January 3, 2023
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Eduardo Marban, Lilian Grigorian
  • Patent number: 11538150
    Abstract: The invention relates to a method of detecting symptoms of peritonitis, wherein the method comprises the following steps: taking a photo of a drainage solution and/or of a catheter exit site using a smartphone and/or inputting at least one query parameter which is input by a patient through the input zone of a smartphone; and, evaluating the photo and/or the query parameter.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: December 27, 2022
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Andreas Wuepper, Ulrich Moissl
  • Patent number: 11525135
    Abstract: The invention relates to a composition comprising a double-stranded RNA (dsRNA) having two complementary strands, comprising at least one block of poly A and the complementary block of poly U, each strand having a length of between 50 and 200 bases, preferably between 55 and 200 bases, and a pharmaceutically acceptable vehicle, carrier or excipient, for use in a method of treating a cancer expressing a TLR3 receptor.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: December 13, 2022
    Assignee: TOLLYS
    Inventors: Marc Bonnin, Sylvain Thierry
  • Patent number: 11521168
    Abstract: A first terminal determines a collection date of a somatic cell based on a desired collection date and a collectable date transmitted by a second medium; and outputs the collection date to a first medium. A second terminal outputs the collectable date to the second medium; and determines an acceptance date based on the collection date transmitted by the first medium and a production period of an iPS cell transmitted by a third medium. A third terminal determines the production period based on the collection date and a producible period, and determines a shipment date based on the production period and stockable location and period transmitted by a fourth medium; and outputs the production period to the third medium. A fourth terminal outputs the stockable location and period to the fourth medium; and determines stock location and period based on the production period and the stockable location and period.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: December 6, 2022
    Assignees: FANUC CORPORATION, I PEACE, INC.
    Inventors: Koji Tanabe, Kiyonori Inaba, Masaru Oda
  • Patent number: 11514389
    Abstract: A system for an iPS cell bank includes a terminal and a server. The terminal receives and sends a production request including a desired collection date of a somatic cell and a customer ID to the server. The server stores a collectable date for collecting the somatic cell, a producible period for producing an iPS cell, and a location and a stockable period for stocking the iPS cell; and determines: a collection date based on the desired collection date and the collectable date; a production period based on the collection date and the producible period; an acceptance date of the somatic cell based on the collection date and the production period; a stock location and a stock period based on the production period, the stockable location, and the stockable period; and a shipment date of the iPS cell based on the production period, the stockable location, and the stockable period.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: November 29, 2022
    Assignees: FANUC CORPORATION, I PEACE, INC.
    Inventors: Koji Tanabe, Kiyonori Inaba, Masaru Oda
  • Patent number: 11464804
    Abstract: A method of treating spinal cord injuries in a patient using sagittal MR images of the spinal cord injury to guide the extent of exposure of the neuro/orthopedic surgeon during a posterior spinal fusion for the purpose of autologous stem cell therapy in the setting of spinal injury; the method using large volumes of the patient's bone marrow aspirated to yield a large quantity of heterogeneous autologous stem cell concentrate containing cellular and subcellular fractions, in addition to soluble protein factors (defined as heterogeneous concentrate) exhibiting regenerative potential which is then applied directly over the spinal cord (under the dura/arachnoid) in the areas affected.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: October 11, 2022
    Inventors: Enrico Stazzone, Madelyn Stazzone
  • Patent number: 11447746
    Abstract: The present invention relates to a method for inducing amplification of human type I NKT cells in vitro using a “specific stimulant+staged cytokine” mode, which consists of two culture stages, wherein the first culture stage focuses on specific amplification of the number of the type I NKT cells, in which a specific stimulant ?-GalCer is used to advantageously amplify the type I NKT cells and ?-GalCer-loaded CD1d-expressing cells are used to stimulate continuous proliferation of the type I NKT cells while adding cytokines IL-2 and IL-7 to assist growth of the type I NKT cells; and the second culture stage is to synchronously perform amplification of the number of the type I NKT cells and guide directed function differentiation, in which CD1d-expressing cells incubated with ?-GalCer continue to stimulate proliferation of the type I NKT cells while adding IL-2, IL-7 and IL-15 to assist amplification of the type I NKT cells and guide differentiation, and IL-12 is added to the culture system 1-2 days before the e
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 20, 2022
    Assignee: Shanghai Innovative Chang'An Biological Technology Co., Ltd.
    Inventors: Jianqing Xu, Xiaoyan Zhang, Jing Wang, Lingyan Zhu
  • Patent number: 11389484
    Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: July 19, 2022
    Assignee: Mesoblast International Sárl
    Inventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
  • Patent number: 11319528
    Abstract: Disclosed herein, are recombinant polypeptides comprising one or more homologous amino acid repeats; and, non-immunogenic bioconjugates comprising recombinant polypeptides comprising one or more homologous amino acid repeats and one or more therapeutic agents. Also, disclosed herein are pharmaceutical compositions including the recombinant polypeptides; and methods of administering the recombinant polypeptides to patients for the treatment of cancer or infections.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: May 3, 2022
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventor: Tara L. Deans
  • Patent number: 11248209
    Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: February 15, 2022
    Assignee: CoImmune, Inc.
    Inventors: Don Healey, Irina Tcherepanova, Melissa Adams
  • Patent number: 11219645
    Abstract: Tumor infiltrating lymphocytes (TILs) are white blood cells that are actively recruited to the tumor site to mount an immune response against tumor growth and metastasis. The disclosure provides methods for treating cancer that comprise steps of isolating CD8+ T cells from a sample derived from a subject, expanding the CD8+ T cells in the presence of interleukin-10, and ad ministering the expanded CD8+ T cells to the subject. Methods of treating cancer may be used in combination with inhibitors of the complement signaling pathway.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: January 11, 2022
    Assignee: Duke University
    Inventors: You-Wen He, Yu Wang
  • Patent number: 11213576
    Abstract: The invention disclosed herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues by first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing necrosis or apoptosis in a tumor or pathogen infected lesion by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue, and then delivering one or more doses of allogeneic cells (e.g., Th1 cells) within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: January 4, 2022
    Assignee: MIRROR BIOLOGICS, INC.
    Inventor: Michael Har-Noy
  • Patent number: 11185348
    Abstract: A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: November 30, 2021
    Assignee: PROGENA INC.
    Inventors: Alexander Feskov, Irina Feskova, Ievgeniia Zhylkova, Stanislav Zhilkov
  • Patent number: 11174461
    Abstract: The invention relates to a method for producing a mesenchymal stem cell (MSC), the method comprising culturing a primitive mesoderm cell in a mesenchymal colony forming medium (M-CFM) comprising LiCl and FGF2, but excluding PDGF, under normoxic conditions for sufficient time for a mesenchymal colony to form, and culturing the mesenchymal colony adherently to produce the MSC, wherein the MSC has superior T-cell immunosuppressive properties relative to an MSC not produced in said M-CFM. The invention also relates to an MSC produced by the method, a population of MSCs produced by the method, a therapeutic composition comprising the MSC produced by the method, an M-CFM and an M-CFM in concentrated form, and method and uses of the MSC or population in treating a disease.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: November 16, 2021
    Assignee: Cynata Therapeutics Limited
    Inventors: Igor Slukvin, Gene Uenishi, Derek Hei, Diana Drier
  • Patent number: 11162073
    Abstract: Described in the present application are methods for preparing populations of hematopoietic stem cells (HSCs), e.g., autologous and/or allogenic HSCs, using mechanical stretching or Trpv4 agonisists, and methods of use of the HSCs in transplantation. In some embodiments, the methods include providing a population comprising hemogenic endothelial (HE) cells, and (i) contacting the HE cells with an amount of an agonist of transient receptor potential cation channel-subfamily vanilloid member 4 (Trpv4); and/or (ii) subjecting the cells to cyclic 2-dimensional stretching, for a time and under conditions sufficient to stimulating endothelial-to-HSC transition. Also provided herein are methods for treating subjects who have, bone marrow, metabolic, and immune diseases; the methods include administering to the subject a therapeutically effective amount of hematopoietic stem cells (HSCs) obtained by a method described herein.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 2, 2021
    Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation
    Inventors: Dhvanit I. Shah, George Q. Daley
  • Patent number: 11154573
    Abstract: Methods and composition for production of T cells are provided. Also provided are therapeutic methods using engineered T cells. For example, in certain aspects methods include preparing three dimensional cell culture compositions comprising stroma cells and hematopoietic stem or progenitor cells in a serum-free medium for producing T cells.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 26, 2021
    Assignee: The Regents of the University of California
    Inventors: Gay M. Crooks, Amélie Montel-Hagen, Christopher Seet
  • Patent number: 11096997
    Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: August 24, 2021
    Assignees: President and Fellows of Harvard College, Regents of the University of Michigan
    Inventors: David J. Mooney, Omar Abdel-Rahman Ali, Eduardo Alexandre Barros E Silva, Hyun Joon Kong, Elliot Earl Hill, Jr., Tanyarut Boontheekul
  • Patent number: 11028180
    Abstract: Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: June 8, 2021
    Assignee: AMGEN INC.
    Inventors: Brian D. Bennett, Chadwick T. King, Jonathan Phillips
  • Patent number: 10967054
    Abstract: Provided is a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Also provided are precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual, methods of preparing the activated T cells, methods of monitoring the treatment, methods of cloning tumor-specific T cell receptors, an isolated population of cells comprising the activated T cells, and compositions and kits useful for cancer immunotherapy.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: April 6, 2021
    Assignee: SYZ CELL THERAPY CO.
    Inventors: Xiangjun Zhou, Jin Li, Yanyan Han, Dongyun Wu, Junyun Liu, Longqing Tang
  • Patent number: 10889809
    Abstract: The present disclosure provides the sequence of a Paenibacillus polymyxa preproenzyme which is the precursor of a neutral protease, expression thereof in a transformed host organism, and methods for production of the neutral protease, by recombinant means. Further, use of the recombinantly produced neutral protease is disclosed in the field of cell biology, particularly for the purpose of tissue dissociation. The disclosure also includes blends with other proteases. Further disclosed are nucleotide sequences encoding the neutral protease.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: January 12, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Thomas Greiner-Stoeffele, Stefan Schoenert
  • Patent number: 10864259
    Abstract: Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: December 15, 2020
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian C. Turner, Gregory Alan Bird
  • Patent number: 10792309
    Abstract: The present invention relates to a cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory T-cells as an active ingredient. By infusing mesenchymal stem cells and immunoregulatory T-cells, which are the cellular therapeutic agent of the present invention, into bone marrow transplant animals, rejection to the host is suppressed after the engraftment of the transplanted bone-marrow to thus obtain the effect of reducing graft-versus-host disease and immune disease. Moreover, the effect of such GVHD reduction is much greater than the one obtained when only mesenchymal stem cells are infused. Accordingly, the cell therapy composition of the present invention having the above-mentioned effects can be useful in the prevention or treatment of immune disease.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: October 6, 2020
    Assignee: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Mi La Cho, Seok-Goo Cho, Jung-Yeon Lim, Hyun-Sil Park, Min-Jung Park
  • Patent number: 10780096
    Abstract: The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 22, 2020
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventors: Patricius Henrikus Cornelis Van Berkel, Philip Wilson Howard, John Hartley
  • Patent number: 10731130
    Abstract: The present invention it was determined that dendritic cells could be derived from various sources including peripheral blood monocytes in the presence of only GM-CSF without other cytokines if the monocytes were not activated. By preventing activation, such as by preventing binding of the cells to the surface of the culture vessel, the monocytes do not require the presence of additional cytokines, such as IL-4 or IL-13, to prevent differentiation into a non-dendritic cell lineage. The immature DCs generated and maintained in this manner were CD14 and expressed high levels of CD1a. Upon maturation by contact with an agent such as, for example, BCG and IFN?, the cells were determined to express surface molecules typical of mature dendritic cells purified by prior methods and cultured in the presence of GM-CSF and IL-4.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: August 4, 2020
    Assignee: NORTHWEST BIOTHERAPEUTICS, INC.
    Inventors: Benjamin A. Tjoa, Marnix L. Bosch
  • Patent number: 10731129
    Abstract: Artificial tissue constructs (TCs), methods of making the TCs, uses thereof, and kits comprising the TCs are provided. TCs are useful for vaccine evaluation for human adult, human non-newborn, and newborns.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: August 4, 2020
    Assignee: Children's Medical Center Corporation
    Inventors: Guzman Sanchez-Schmitz, Ofer Levy, Chad Stevens
  • Patent number: 10709762
    Abstract: The invention relates to methods and compositions comprising a macrophage colony stimulating factor (M-CSF) polypeptide or an agonist of the M-CSF receptor for preventing or treating myeloid cytopenia and related complications (such as infections) in a patient in need thereof (such as a patient undergoing hematopoietic stem cell transplantation).
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: July 14, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'AIX-MARSEILLE
    Inventor: Michael Sieweke
  • Patent number: 10683482
    Abstract: Methods of producing stem cell conditioned media to treat mammalian injuries or insults. In at least one embodiment of a method of producing a stem cell conditioned media of the present disclosure, the method comprises the steps of culturing at least one stem cell in a first cell culture medium, replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one stem cell in the second cell culture medium, and collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains a cell culture byproduct effective to treat a mammalian insult or injury.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: June 16, 2020
    Assignee: NeuroFx, Inc.
    Inventors: Keith Leonard March, Brian H. Johnstone, Yansheng Du
  • Patent number: 10626372
    Abstract: The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, and NK cells.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: April 21, 2020
    Assignee: FATE THERAPEUTICS, INC.
    Inventors: Bahram Valamehr, Raedun Clarke
  • Patent number: 10584312
    Abstract: The present invention relates to a method for isolating pluripotent/multipotent stem cells derived from umbilical cord blood, characterized by culturing mononuclear cells isolated from umbilical cord blood in a culture vessel containing fibronectin and then harvesting stem cells from the culture, the umbilical cord blood-derived pluripotent/multipotent stem cells isolated thereby; and a cell therapeutic agent containing the pluripotent/multipotent stem cells derived from umbilical cord blood or cells differentiated therefrom. The present invention also relates to a novel culture media for stem cells, a culture method for stem cells which is characterized by culturing and proliferating stem cells in the culture media, and a method for increasing sternness of stem cells which is characterized by a sphere culture or a three-dimensional culture of stem cells.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: March 10, 2020
    Assignee: SNU R&DB FOUNDATION
    Inventors: Kyung Sun Kang, Kyoung Hwan Roh
  • Patent number: 10370642
    Abstract: The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: August 6, 2019
    Inventor: Robert Sackstein
  • Patent number: 10287579
    Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: May 14, 2019
    Assignees: Ospedale San Raffaele S.r.l., Fondazione Telethon
    Inventors: Alessandra Biffi, Bernhard Rudolf Gentner, Luigi Naldini
  • Patent number: 10273503
    Abstract: Methods and compositions for enhancing viral gene transfer, such as lentiviral gene transfer, and improving the efficacy of gene delivery to cells such as primitive hematopoietic cells, are described. These methods and compositions are based on the use of pyrimido[4,5-b]indole derivatives. Cell-based compositions and methods useful for therapeutic indications amenable to treatment with gene therapies, including hematopoietic stem cell therapies, are also described.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: April 30, 2019
    Assignees: UNIVERSITE DE MONTREAL, BRITISH COLUMBIA CANCER AGENCY BRANCH, FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Guy Sauvageau, Keith Richard Humphries, Hans-Peter Kiem, Iman Fares, Jalila Chagraoui
  • Patent number: 10195044
    Abstract: The disclosure relates to an intervertebral disc implant comprising a first construct comprising a continuous layer of nucleus pulposus (NP) tissue directly or indirectly on and integrated with a substrate, and a second construct surrounding the first construct comprising one or more continuous layers of annulus fibrosus (AF) tissue on and adherent to a scaffold, wherein the AF tissue, which is composed of single or multiple adherent layers, is integrated with the NP tissue. The disclosure also relates to methods of preparing the multi-tissue intervertebral disc and using the intervertebral disc as an implant.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: February 5, 2019
    Assignee: Sinai Health System
    Inventors: Rita Kandel, J. Paul Santerre, Shu Qiu Li
  • Patent number: 10188099
    Abstract: The current disclosure provides a method for the creation of a high-density cryopreserved cell bank using perfusion culture techniques and non-centrifugal concentration of cells. Methods of production using this high-density cryopreserved cell bank are also provided.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 29, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Xiaoxia Jin, Haodi Dong, Claudia Buser
  • Patent number: 10184108
    Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 22, 2019
    Assignee: Argos Therapeutics, Inc.
    Inventors: Don Healey, Irina Tcherepanova, Melissa Adams, Mark Debenedette
  • Patent number: 10173216
    Abstract: A particle capture system that can be used in the context of a lab-on-a-chip platform for particle- and cell-based assays is described. The system comprises a capture chamber comprising a plurality of capture sites, the capture sites defining a capture area configured to receive individual particles travelling within the capture chamber. By rotating the chamber, the individual particles are biased towards the capture sites where they may be captured.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: January 8, 2019
    Assignee: DUBLIN CITY UNIVERSITY
    Inventors: Jens Ducree, Robert Burger
  • Patent number: 10149897
    Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: December 11, 2018
    Assignees: President and Fellows of Harvard College, Regents of the University of Michigan
    Inventors: David J. Mooney, Omar Abdel-Rahman Ali, Eduardo Alexandre Barros E Silva, Hyun Joon Kong, Elliot Earl Hill, Jr., Tanyarut Boontheekul
  • Patent number: 10137184
    Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: November 27, 2018
    Assignees: President and Fellows of Harvard College, Regents of the University of Michigan
    Inventors: David J. Mooney, Omar Abdel-Rahman Ali, Eduardo Alexandre Barros E Silva, Hyun Joon Kong, Elliot Earl Hill, Jr., Tanyarut Boontheekul
  • Patent number: 10004701
    Abstract: Provided herein are compositions and methods for treating or preventing infection.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 26, 2018
    Assignees: UNIVERSITY OF ROCHESTER, UNIVERSITY OF KANSAS
    Inventors: Paul M. Dunman, Damian J. Krysan, Daniel P. Flaherty
  • Patent number: 9993503
    Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: June 12, 2018
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
  • Patent number: 9993537
    Abstract: Certain embodiments of the invention are directed to methods for inducing an immunologic response to a tumor in a patient using mature dendritic cells transfected with a nucleic acid composition encoding one or more tumor antigens and loaded with a corresponding tumor antigen composition.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: June 12, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: William K. Decker, Elizabeth J. Shpall, Krishna V. Komanduri, Dongxia Xing
  • Patent number: 9969977
    Abstract: Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and to formulate pharmaceutical compositions. In a further embodiment, a substantially homogenous population of cells which co-express CD49c, CD90 and at least one cardiac-related transcription factor is made and can be used to treat a human suffering from a cardiac condition.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: May 15, 2018
    Assignee: GARNET BIOTHERAPEUTICS
    Inventors: Tony W. Ho, Gene C. Kopen, William F. Righter, J. Lynn Rutkowski, Joseph Wagner, W. Joseph Herring, Vanessa Ragaglia
  • Patent number: 9937208
    Abstract: The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4+ and CD8+ T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1?, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: April 10, 2018
    Assignee: ABT Holding Company
    Inventor: Robert W. Mays
  • Patent number: 9910039
    Abstract: The present specification discloses regulatory T cells, compositions including regulatory T cells, methods of identifying, isolating, enriching, obtaining, and/or expanding regulatory T cells or subset populations thereof, kits including components useful for performing such methods, and methods of treating an immune-based disorder in an individual by administering regulatory T cells or compositions comprising such regulatory T cells to an individual in need thereof.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: March 6, 2018
    Assignee: Beckman Coulter, Inc.
    Inventor: Carlos A. Garcia Santana
  • Patent number: 9910935
    Abstract: A bioassembly system having a tissue/object modeling software component fully and seamlessly integrated with a robotic bioassembly workstation component for the computer-assisted design, fabrication and assembly of biological and non-biological constructs. The robotic bioassembly workstation includes a six-axis robot providing the capability for oblique-angle printing, printing by non-sequential planar layering, and printing on print substrates having variable surface topographies, enabling fabrication of more complex bio-constructs including tissues, organs and vascular trees.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: March 6, 2018
    Assignee: Advanced Solutions Life Sciences, LLC
    Inventors: Michael Golway, Justin C. Palmer, Jeffrey Kyle Eli, Joshua D. Bartlett, Ellsworth H. Collins
  • Patent number: 9834755
    Abstract: The present invention relates to methods, kits and compositions for expansion of hematopoietic stem/progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. Also provided herein are methods for expanding the hematopoietic stem/progenitor cells using kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. The hematopoietic stem/progenitor cells expanded using the disclosed kits, compositions and methods include human umbilical cord blood stem/progenitor cells, placental cord blood stem/progenitor cells and peripheral blood stem cells. The present invention also relates to administering hematopoietic stem/progenitor cells expanded using a combination of a Notch agonist and an aryl hydrocarbon receptor antagonist to a patient for short-term and/or long-term in vivo repopulation benefits.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: December 5, 2017
    Assignees: Fred Hutchinson Cancer Research Center, Novartis AG
    Inventors: Irwin D. Bernstein, Anthony E. Boitano, Michael Cooke, Colleen Delaney
  • Patent number: 9834752
    Abstract: The present invention relates to a method for in vitro expansion of mature erythroid cells. More specifically, the present invention relates to a method for obtaining concentrated erythrocytes by culturing erythroid cells at high density so as to allow the cells to physically and directly come in contact with each other. Particularly, the method of the present invention is very useful in that it is possible to obtain a large amount of clinically useful concentrated erythrocytes through a small container such as a test tube-sized bioreactor.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: December 5, 2017
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Eun-Jung Baek, Hye-Sook Choi
  • Patent number: 9783778
    Abstract: The description discloses a device and a kit adapted for selection of cells that are resistant to receptor-mediated apoptosis and a method for using the device and kit. The device enables negative selection of mature immune cells which induce graft versus host disease (GvHD) out of a heterogeneous cell population which is introduced into the device. The device enables an efficient cell selection in simplified and cheaper setting by an off the shelf product—a solution that currently do not exist. The description further discloses uses for the device.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: October 10, 2017
    Assignee: Cellect Biotherapeutics Ltd.
    Inventors: Shai Yarkoni, Nadir Askenasy